TCM
ESPR

Tekla Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Tekla Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-102,800
Closed -$2.42M – 143
2015
Q3 		$2.42M Sell
102,800
-45,200
-31% -$2.84M 0.09% 136
2015
Q2 		$12.1M Buy
+148,000
New +$14.5M 0.44% 47

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Tekla Capital Management's ESPR Position: Q1 2021 in Review

Tekla Capital Management sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 41,577 shares — an estimated $1.08M sold.

Tekla Capital Management first reported a position in ESPR in Q2 2015 and held it in 19 quarters. The position peaked at $13.7M in Q1 2018. 155 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • Tekla Capital Management reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Tekla Capital Management sold 41,577 Esperion Therapeutics shares in Q1 2021, an estimated $1.08M.
  • Tekla Capital Management first reported a position in Esperion Therapeutics in Q2 2015 and held it in 19 quarters.
  • Tekla Capital Management's Esperion Therapeutics position peaked at $13.7M in Q1 2018.
  • 155 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Tekla Capital Management's 13F filing for Q1 2021, filed 14 May 2021.